Science2019globalhigh confidence

In a small phase I clinical trial, a combination of the cancer drug dasatinib and the plant pigment quercetin eliminated senescent cells from the tissues of people with diabetic kidney disease.

Notes on verification

Confirmed by peer-reviewed primary source (Hickson et al., EBioMedicine 2019) and corroborating secondary sources. Claim's phrase 'eliminated' overstates the actual finding of significant reduction rather than complete elimination; trial was small (n=9) and open-label, limiting generalizability. [tier=gold indep_score=0.983 clusters=3 claim_tier=notable]

Sources